IL18R1 and experimental autoimmune encephalomyelitis: By acting through IL-18Rα and IL-1R8, neurological deficits and myelin loss in the experimental autoimmune encephalomyelitis model, an extensively used model for multiple sclerosis, were protected by the treatment of rhIL-37 (57).